CNST - Eyes on Constellation Pharma after ASH conference presentation on CPI-0610 for myelofibrosis

Source: Press release"We are pleased both with the response rates and consistency of the results we are seeing in MANIFEST,"says Constellation Pharmaceuticals (CNST) CEO Jigar Raythatha. "In addition, we are excited by results from our translational studies that suggest that CPI-0610 may potentially be a disease modifying therapy that affects all four hallmarks of myelofibrosis."The Phase 2 MANIFEST trial showed 42 of 63 evaluable patients (67%) achieved a ?35% reduction in spleen volume ((SVR35)) at 24 weeks (the primary endpoint for Arm 3). 34 of 60 evaluable patients (57%) achieved a ?50% reduction in Total Symptom Scores ((TSS50)) at 24 weeks. The median TSS reduction was 59%.CPI-0610 was generally well tolerated in MANIFEST, both as monotherapy and in combination with ruxolitinib, and in both JAK-inhibitor-naïve and -ineligible as well as JAK-inhibitor-experienced patients.Next up is MANIFEST-2, a global, double-blind, randomized Phase 3 clinical study with CPI-0610 in combination with ruxolitinib versus placebo plus ruxolitinib

For further details see:

Eyes on Constellation Pharma after ASH conference presentation on CPI-0610 for myelofibrosis